共 52 条
[1]
Basch E(2011)American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 29 4189-4198
[2]
Prestrud AA(2016)2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients Ann Oncol 27 v119-v133
[3]
Hesketh PJ(2015)Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan Int J Clin Oncol 20 855-865
[4]
Roila F(2016)A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin’s lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists Int J Hematol 104 378-383
[5]
Molassiotis A(1995)The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro Br J Pharmacol 114 851-859
[6]
Herrstedt J(2008)Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor Anesth Analg 107 469-478
[7]
Tamura K(2009)Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial Lancet Oncol 10 115-124
[8]
Aiba K(2016)Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study Ann Oncol 27 1601-1606
[9]
Saeki T(2011)Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin’s lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL) Support Care Cancer 19 1505-1510
[10]
Takahashi T(2014)Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy Leuk Lymphoma 55 544-550